Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project
Authors:
Open Access
- 19 October 2026
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- p. 1-21
Abstract
No abstract availableKeywords
Funding Information
- LEO Pharma
This publication has 42 references indexed in Scilit:
- Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab EmiratesDermatology and Therapy, 2024
- Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendationsAnnals of Allergy, Asthma & Immunology, 2023
- Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapiesJournal of the American Academy of Dermatology, 2023
- Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2023
- Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspectiveJournal of the American Academy of Dermatology, 2023
- Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialJournal of the American Academy of Dermatology, 2022
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020
- Atopic dermatitisThe Lancet, 2020
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet, 2020
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017